
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort is well-positioned for long-term revenue growth, with a strong pipeline of commercial and clinical customers in the growing cell and gene therapy market. The company also has a focus on expanding its services and products, which could lead to margin expansion in the coming years. Additionally, CryoPort's revenue visibility is high and its revenue quality is strong, providing stability for future growth.
Bears say
CryoPort is expected to see improving revenue growth driven by the recovery of the market and approvals of new cell and gene therapies. However, there are concerns about the company's ability to turn profitable as it continues to incur high operating expenses. There is also a risk of potential impairment and the stock appears overvalued compared to its peers. Ultimately, the success of CryoPort will depend on the pace of commercialization of cell and gene therapies, but the company's high valuation and operating expenses are a cause for concern.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares